



## Clinical trial results:

### Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine BMD (Bone Mineral Density) in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip Fracture Summary

EudraCT number	2008-002693-35
Trial protocol	DK DE GB ES IT GR SE AT FR CZ IE FI NO
Global end of trial date	20 August 2015

#### Results information

Result version number	v2 (current)
This version publication date	27 November 2016
First version publication date	31 July 2016
Version creation reason	<ul style="list-style-type: none"><li>• Correction of full data set</li></ul> Correction needed to full data set.

#### Trial information

##### Trial identification

Sponsor protocol code	12400
-----------------------	-------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00887354
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Alias: B3D-EW-GHDK, Trial ID: 12400

Notes:

#### Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon-Fri 9AM-5PM EST, Eli Lilly and Company, +1 877-CTLilly,
Scientific contact	Available Mon-Fri 9AM-5PM EST, Eli Lilly and Company, +1 877-285-4559,

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

Analysis stage	Final
Date of interim/final analysis	20 August 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	20 August 2015
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

Main objective of the trial:

This study will evaluate whether teriparatide is superior to the active comparator in the change from baseline of lumbar spine BMD (bone mineral density) in men and postmenopausal women with low bone mass and a recent pertrochanteric hip fracture.

Protection of trial subjects:

This study was conducted in accordance with International Code of Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 April 2009
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects****Subjects enrolled per country**

Country: Number of subjects enrolled	France: 13
Country: Number of subjects enrolled	Germany: 3
Country: Number of subjects enrolled	Spain: 40
Country: Number of subjects enrolled	United Kingdom: 1
Country: Number of subjects enrolled	Austria: 1
Country: Number of subjects enrolled	Ireland: 1
Country: Number of subjects enrolled	Sweden: 5
Country: Number of subjects enrolled	Canada: 2
Country: Number of subjects enrolled	Greece: 7
Country: Number of subjects enrolled	Czech Republic: 20
Country: Number of subjects enrolled	United States: 5
Country: Number of subjects enrolled	Norway: 7
Country: Number of subjects enrolled	Denmark: 22
Country: Number of subjects enrolled	Italy: 26
Country: Number of subjects enrolled	Mexico: 18
Worldwide total number of subjects	171
EEA total number of subjects	146

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	12
From 65 to 84 years	131
85 years and over	28

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Full Analysis Set (FAS) is defined as all randomized participants receiving at least one dose of study drug with at least one post-baseline efficacy measure.

### Period 1

Period 1 title	Treatment Phase (Week 0 to Week 26)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Teriparatide

Arm description:

20 microgram (mcg) a day by subcutaneous (SC) injection treatment phase throughout study (Week 0 to Week 26).

Calcium: Approximately 500 to 1000 milligram per day (mg/day) administered orally throughout study.

Vitamin D: Approximately 800 International Units per day (IU/day) administered orally throughout study.

Arm type	Experimental
Investigational medicinal product name	Teriparatide
Investigational medicinal product code	
Other name	LY333334, Forteo, Forsteo
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

20 micrograms (mcg) a day by subcutaneous injection throughout study.

Investigational medicinal product name	Calcium
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Approximately 500 to 1000 mg/day administered orally throughout study.

Investigational medicinal product name	Vitamin D
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Approximately 800 International Units per day (IU/day) administered orally throughout study.

Investigational medicinal product name	Oral Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet

Routes of administration	Oral use
Dosage and administration details: Weekly 35mg oral placebo	
<b>Arm title</b>	Risedronate
Arm description: 35 mg risedronate sodium orally once weekly throughout study.  Calcium: Approximately 500 to 1000 mg/day administered orally throughout study.  Vitamin D: Approximately 800 International Units per day (IU/day) administered orally throughout study.	
Arm type	Active comparator
Investigational medicinal product name	Risedronate
Investigational medicinal product code	
Other name	Actonel
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 35 milligrams (mg) risedronate sodium orally once weekly throughout study.	
Investigational medicinal product name	Calcium
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: Approximately 500 to 1000 mg/day administered orally throughout study.	
Investigational medicinal product name	Vitamin D
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: Approximately 800 International Units per day (IU/day) administered orally throughout study.	
Investigational medicinal product name	Daily Placebo Injection
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use
Dosage and administration details: Placebo 20 micrograms (mcg) daily	

<b>Number of subjects in period 1</b>	Teriparatide	Risedronate
Started	111	113
Included in Full Analysis Set	86	85
Completed	86	85
Not completed	25	28

Lack of efficacy	20	25
Not treated	5	3

## Period 2

Period 2 title	Treatment Phase FAS (Week 0 to Week 26)
Is this the baseline period?	Yes <sup>[1]</sup>
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Carer, Assessor, Subject

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Teriparatide

Arm description:

20 microgram (mcg) a day by subcutaneous (SC) injection throughout study (FAS Week 0 to Week 26).

Calcium: Approximately 500 to 1000 milligram per day (mg/day) administered orally throughout study.

Vitamin D: Approximately 800 International Units per day (IU/day) administered orally throughout study.

Arm type	Experimental
Investigational medicinal product name	Teriparatide
Investigational medicinal product code	
Other name	LY333334, Forteo, Forsteo
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

20 micrograms (mcg) a day by subcutaneous injection throughout study.

Investigational medicinal product name	Calcium
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Approximately 500 to 1000 milligram per day (mg/day) administered orally throughout study.

Investigational medicinal product name	Vitamin D
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Approximately 800 International Units per day (IU/day) administered orally throughout study.

Investigational medicinal product name	Oral Placebo
Investigational medicinal product code	
Other name	

Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Weekly 35mg oral placebo	
<b>Arm title</b>	Risedronate
Arm description:	
35 mg risedronate sodium orally once weekly throughout study.	
Calcium: Approximately 500 to 1000 mg/day administered orally throughout study.	
Vitamin D: Approximately 800 International Units per day (IU/day) administered orally throughout study.	
Arm type	Active comparator
Investigational medicinal product name	Risedronate
Investigational medicinal product code	
Other name	Actonel
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
35 mg risedronate sodium orally once weekly throughout study.	
Investigational medicinal product name	Calcium
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Approximately 500 to 1000 mg/day administered orally throughout study.	
Investigational medicinal product name	Vitamin D
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Approximately 800 International Units per day (IU/day) administered orally throughout study.	
Investigational medicinal product name	Daily Placebo Injection
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
Placebo 20 micrograms (mcg) daily	
Notes:	
[1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.	
Justification: Period 1 accounts for the number of participants who were randomized and received at least one dose of study drug. Period 2 is the baseline period as it reports the efficacy results based on the FAS population, which is defined as those participants who received at least one dose of study drug with at least one post-baseline efficacy measure.	

Number of subjects in period 2	Teriparatide	Risedronate
Started	86	85
Completed	60	65
Not completed	26	20
Physician decision	2	1
Consent withdrawn by subject	14	8
Adverse event, non-fatal	3	3
Death	-	1
Caregiver decision	1	2
Sponsor decision	1	1
Lost to follow-up	2	1
Entry criteria not met	3	3

### Period 3

Period 3 title	Open Label Phase (Week 26 to Week 78)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Teriparatide

Arm description:

20 microgram (mcg) a day by subcutaneous (SC) injection throughout study (Open Label Phase Week 26 to Week 78).

Calcium: Approximately 500 to 1000 milligram per day (mg/day) administered orally throughout study.

Vitamin D: Approximately 800 International Units per day (IU/day) administered orally throughout study.

Arm type	Experimental
Investigational medicinal product name	Teriparatide
Investigational medicinal product code	
Other name	LY333334, Forteo, Forsteo
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

20 micrograms (mcg) a day by subcutaneous injection throughout study.

Investigational medicinal product name	Calcium
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Approximately 500 to 1000 mg/day administered orally throughout study.



Investigational medicinal product name	Vitamin D
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Approximately 800 International Units per day (IU/day) administered orally throughout study.	
<b>Arm title</b>	Risedronate

Arm description:

35 mg risedronate sodium orally once weekly throughout study.

Calcium: Approximately 500 to 1000 mg/day administered orally throughout study.

Vitamin D: Approximately 800 International Units per day (IU/day) administered orally throughout study.

Arm type	Active comparator
Investigational medicinal product name	Risedronate
Investigational medicinal product code	
Other name	Actonel
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

35 milligrams (mg) risedronate sodium orally once weekly throughout study.

Investigational medicinal product name	Calcium
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Approximately 500 to 1000 mg/day administered orally throughout study.

Investigational medicinal product name	Vitamin D
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Approximately 800 International Units per day (IU/day) administered orally throughout study.

<b>Number of subjects in period 3</b>	Teriparatide	Risedronate
Started	60	65
Completed	57	59
Not completed	3	6
Consent withdrawn by subject	1	2
Physician decision	-	1
Adverse event, non-fatal	1	-
Death	-	2
Lost to follow-up	1	1



## Baseline characteristics

### Reporting groups

Reporting group title	Teriparatide
-----------------------	--------------

Reporting group description:

20 microgram (mcg) a day by subcutaneous (SC) injection throughout study (FAS Week 0 to Week 26).

Calcium: Approximately 500 to 1000 milligram per day (mg/day) administered orally throughout study.

Vitamin D: Approximately 800 International Units per day (IU/day) administered orally throughout study.

Reporting group title	Risedronate
-----------------------	-------------

Reporting group description:

35 mg risedronate sodium orally once weekly throughout study.

Calcium: Approximately 500 to 1000 mg/day administered orally throughout study.

Vitamin D: Approximately 800 International Units per day (IU/day) administered orally throughout study.

Reporting group values	Teriparatide	Risedronate	Total
Number of subjects	86	85	171
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	8	4	12
From 65-84 years	62	69	131
85 years and over	16	12	28
Age Continuous Units: years			
arithmetic mean	77.2	76.4	
standard deviation	± 7.96	± 7.47	-
Gender, Male/Female Units: participants			
Female	66	66	132
Male	20	19	39
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	86	85	171
More than one race	0	0	0
Unknown or Not Reported	0	0	0

Region of Enrollment			
Number of participants for Country/Region of Enrollment reflects FAS population.			
Units: Subjects			
Greece	3	4	7
Canada	0	2	2
Czech Republic	8	12	20
United States	1	4	5
Norway	5	2	7
Denmark	13	9	22
Italy	16	10	26
Mexico	6	12	18
France	5	8	13
Germany	2	1	3
Spain	21	19	40
United Kingdom	1	0	1
Austria	1	0	1
Ireland	1	0	1
Sweden	3	2	5

## End points

---

### End points reporting groups

Reporting group title	Teriparatide
-----------------------	--------------

Reporting group description:

20 microgram (mcg) a day by subcutaneous (SC) injection treatment phase throughout study (Week 0 to Week 26).

Calcium: Approximately 500 to 1000 milligram per day (mg/day) administered orally throughout study.

Vitamin D: Approximately 800 International Units per day (IU/day) administered orally throughout study.

Reporting group title	Risedronate
-----------------------	-------------

Reporting group description:

35 mg risedronate sodium orally once weekly throughout study.

Calcium: Approximately 500 to 1000 mg/day administered orally throughout study.

Vitamin D: Approximately 800 International Units per day (IU/day) administered orally throughout study.

Reporting group title	Teriparatide
-----------------------	--------------

Reporting group description:

20 microgram (mcg) a day by subcutaneous (SC) injection throughout study (FAS Week 0 to Week 26).

Calcium: Approximately 500 to 1000 milligram per day (mg/day) administered orally throughout study.

Vitamin D: Approximately 800 International Units per day (IU/day) administered orally throughout study.

Reporting group title	Risedronate
-----------------------	-------------

Reporting group description:

35 mg risedronate sodium orally once weekly throughout study.

Calcium: Approximately 500 to 1000 mg/day administered orally throughout study.

Vitamin D: Approximately 800 International Units per day (IU/day) administered orally throughout study.

Reporting group title	Teriparatide
-----------------------	--------------

Reporting group description:

20 microgram (mcg) a day by subcutaneous (SC) injection throughout study (Open Label Phase Week 26 to Week 78).

Calcium: Approximately 500 to 1000 milligram per day (mg/day) administered orally throughout study.

Vitamin D: Approximately 800 International Units per day (IU/day) administered orally throughout study.

Reporting group title	Risedronate
-----------------------	-------------

Reporting group description:

35 mg risedronate sodium orally once weekly throughout study.

Calcium: Approximately 500 to 1000 mg/day administered orally throughout study.

Vitamin D: Approximately 800 International Units per day (IU/day) administered orally throughout study.

---

**Primary: Change in Lumbar Spine Areal Bone Mineral Density**

End point title	Change in Lumbar Spine Areal Bone Mineral Density
-----------------	---

End point description:

Least squares (LS) means obtained from mixed model repeated measures analysis including as fixed effects treatment and time with interaction, further adjusted for baseline lumbar spine BMD, type of hip fracture (31-A1/31-A2) and glucocorticoids used at baseline (Yes/No).

End point type	Primary
----------------	---------

End point timeframe:

Baseline, Week 78

End point values	Teriparatide	Risedronate		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61 <sup>[1]</sup>	66 <sup>[2]</sup>		
Units: gram per square centimeter (g/cm <sup>2</sup> )				
least squares mean (standard error)	0.094 (± 0.0075)	0.055 (± 0.0081)		

Notes:

[1] - Post-Baseline Efficacy data was collected for 61 Participants of the 86 participants in the FAS.

[2] - Post-Baseline Efficacy data was collected for 66 Participants of the 85 participants in the FAS.

**Statistical analyses**

<b>Statistical analysis title</b>	Primary Endpoint Statistical Analysis
Comparison groups	Teriparatide v Risedronate
Number of subjects included in analysis	127
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	LS Mean
Point estimate	0.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.025
upper limit	0.055

**Secondary: Change in Lumbar Spine Areal Bone Mineral Density**

End point title	Change in Lumbar Spine Areal Bone Mineral Density
-----------------	---

End point description:

Least squares (LS) means obtained from mixed model repeated measures analysis including as fixed effects treatment and time with interaction, further adjusted for baseline lumbar spine BMD, type of hip fracture (31-A1/31-A2) and glucocorticoids used at baseline (Yes/No).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 26 and Baseline, Week 52

End point values	Teriparatide	Risedronate		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61 <sup>[3]</sup>	66 <sup>[4]</sup>		
Units: g/cm <sup>2</sup>				
least squares mean (standard error)				
Week 26	0.053 (± 0.0074)	0.032 (± 0.0081)		
Week 52	0.078 (± 0.0074)	0.044 (± 0.0081)		

Notes:

[3] - Post-baseline efficacy data was collected for 61 participants of the 86 participants of the FAS.

[4] - Post-baseline efficacy data was collected for 66 participants or the 85 participants of the FAS.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change in Areal Bone Mineral Density Measured at the Femoral Neck and Total Hip of the Non-Fractured Limb

End point title	Change in Areal Bone Mineral Density Measured at the Femoral Neck and Total Hip of the Non-Fractured Limb
-----------------	---

End point description:

Change from baseline in areal bone mineral density at the femoral Neck/Total Hip of the non-fractured limb at 26 weeks, 52 weeks and 78 weeks. Femoral neck BMD: Least squares (LS) means obtained from mixed model repeated measures analysis including as fixed effects treatment and time with interaction, further adjusted for baseline femoral neck BMD and type of hip fracture (31-A1/31-A2) .

Total hip BMD: Least squares (LS) means obtained from mixed model repeated measures analysis including as fixed effects treatment and time with interaction, further adjusted for baseline total hip BMD, type of hip fracture (31-A1/31-A2) and duration of prior bisphosphonate use.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 26; Baseline, Week 52; Baseline, Week 78

End point values	Teriparatide	Risedronate		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	60 <sup>[5]</sup>	61 <sup>[6]</sup>		
Units: g/cm <sup>2</sup>				
least squares mean (standard error)				
Total Hip 26 Weeks	-0.001 (± 0.0042)	-0.001 (± 0.0042)		
Total Hip 52 Weeks	0.001 (± 0.0042)	-0.001 (± 0.0042)		
Total Hip 78 Weeks	0.007 (± 0.0042)	0.005 (± 0.0043)		
Femoral Neck 26 Weeks	0.002 (± 0.0044)	-0.009 (± 0.0043)		
Femoral Neck 52 Weeks	0 (± 0.0044)	-0.006 (± 0.0044)		

Femoral Neck 78 Weeks	0.012 ( $\pm$ 0.0044)	-0.007 ( $\pm$ 0.0045)		
-----------------------	-----------------------	------------------------	--	--

Notes:

[5] - Post-baseline efficacy data was collected for 60 participants of 86 participants in the FAS.

[6] - Post-baseline efficacy data was collected for 61 participants of 85 participants in the FAS.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Short form-36 (SF-36) Questionnaire

End point title	Short form-36 (SF-36) Questionnaire
-----------------	-------------------------------------

End point description:

SF-36 is a self-reported questionnaire consisting of 36 questions covering 8 health domains. Each domain was scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. The physical component summary (PCS) has been constructed based on the 8 SF-36 domains and consist of the physical functioning, bodily pain, role-physical, and general health scales (range = 0 to 100).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, 6, 12, 18, and 26 Weeks of Treatment

End point values	Teriparatide	Risedronate		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	67 <sup>[7]</sup>	65 <sup>[8]</sup>		
Units: units on a scale				
least squares mean (standard error)				
Baseline, Week 6	7.37 ( $\pm$ 1.065)	5.1 ( $\pm$ 1.087)		
Baseline, Week 12	11.32 ( $\pm$ 1.207)	11.09 ( $\pm$ 1.208)		
Baseline, Week 18	14.37 ( $\pm$ 1.256)	12.81 ( $\pm$ 1.26)		
Baseline, Week 26	16.34 ( $\pm$ 1.278)	14.36 ( $\pm$ 1.258)		

Notes:

[7] - Post-baseline efficacy data was collected for 67 participants of 86 participants in the FAS.

[8] - Post-baseline efficacy data was collected for 65 participants of 85 participants in the FAS.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Timed "Up and Go" Test

End point title	Timed "Up and Go" Test
-----------------	------------------------

End point description:

Timed "Up and Go" test measures, in seconds, the time taken by an individual to stand up from a standard chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down. Least squares (LS) means obtained from mixed model repeated measures analysis including as fixed effects treatment and time with interaction, further adjusted for age, type of fracture (31-A1/31-A2), type of reduction (open/close), type of walking aid, baseline SF-36 PCS and baseline Charnley's pain score.

End point type	Secondary
----------------	-----------



End point timeframe:  
6, 12, 18, and 26 Weeks

End point values	Teriparatide	Risedronate		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	79 <sup>[9]</sup>	78 <sup>[10]</sup>		
Units: seconds (sec)				
least squares mean (standard error)				
Week 6	26.45 (± 1.09)	32.38 (± 1.085)		
Week 12	20.13 (± 1.092)	24.48 (± 1.086)		
Week 18	17.75 (± 1.093)	21.14 (± 1.087)		
Week 26	16.69 (± 1.095)	19.91 (± 1.088)		

Notes:

[9] - Post-baseline efficacy data was collected for 79 participants of 86 participants in the FAS.

[10] - Post-baseline efficacy data was collected for 78 participants of 85 participants in the FAS.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Visual Analog Scale

End point title	Visual Analog Scale
End point description:	
Visual analog pain scale is a measurement instrument to measure the level of hip pain. Scores range from 0 to 100 millimeter (mm) with higher score indicating greater pain. Least squares (LS) means obtained from mixed model repeated measures analysis including as fixed effects treatment and time with interaction, further adjusted for type of fracture (31-A1/31-A2), type of reduction (open/close), use of opioids (Yes/No), use of non-steroidal anti-inflammatory drugs, adequate reduction (Yes/No) and interaction between treatment and adequate reduction.	
End point type	Secondary
End point timeframe:	
6, 12, 18, and 26 Weeks	

End point values	Teriparatide	Risedronate		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	63 <sup>[11]</sup>	62 <sup>[12]</sup>		
Units: millimeter (mm)				
least squares mean (standard error)				
Week 6	16.44 (± 3.977)	23.54 (± 4.443)		
Week 12	9.28 (± 4.048)	19.24 (± 4.452)		
Week 18	6.9 (± 4.147)	18.19 (± 4.508)		
Week 26	4.48 (± 4.128)	13.74 (± 4.505)		

Notes:

[11] - Post-baseline efficacy data was collected for 63 participants of 86 participants in the FAS.

[12] - Post-baseline efficacy data was collected for 62 participants of 85 participants in the FAS.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants Reporting Hip Pain in Modification of the Charnley's Pain Scale

End point title	Percentage of Participants Reporting Hip Pain in Modification of the Charnley's Pain Scale
-----------------	--

End point description:

Self-reported hip pain scale in which 0=no pain; 1=pain is slight or intermittent, pain on starting to walk but getting less with normal activity; 2=pain occurs only after some activity, disappears quickly with rest; 3=pain is tolerable, permitting limited activity; 4=pain is severe on attempting to walk, prevents all activity; 5=pain is severe and spontaneous.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline

End point values	Teriparatide	Risedronate		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	85	85		
Units: Percentage of Participants				
number (not applicable)				
0- No Pain	9.4	8.2		
1- Pain slight or intermittent	4.7	12.9		
2- Pain occurs only after some activity	23.5	20		
3- Pain is tolerable	36.5	38.8		
4- Pain severe on attempting to walk	20	15.3		
5- Pain severe and spontaneous	5.9	4.7		

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Treatment

Adverse event reporting additional description:

B3D-EW-GHDK

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18.0
--------------------	------

### Reporting groups

Reporting group title	Teriparatide
-----------------------	--------------

Reporting group description: -

Reporting group title	Risedronate
-----------------------	-------------

Reporting group description: -

Serious adverse events	Teriparatide	Risedronate	
Total subjects affected by serious adverse events			
subjects affected / exposed	21 / 106 (19.81%)	27 / 110 (24.55%)	
number of deaths (all causes)	2	7	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
pancreatic carcinoma metastatic			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Vascular disorders			
aortic stenosis			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
orthostatic hypotension			
alternative dictionary used: MedDRA 18.0			

subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
venous thrombosis			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
chest pain			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
death			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
device breakage			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
device failure			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
medical device complication			
alternative dictionary used: MedDRA 18.0			

subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
bronchial polyp			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
chronic obstructive pulmonary disease			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
dyspnoea			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pleural effusion			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
pneumothorax			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
pulmonary embolism			
alternative dictionary used: MedDRA 18.0			

subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Psychiatric disorders			
confusional state			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
delirium			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
fall			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	6 / 106 (5.66%)	9 / 110 (8.18%)	
occurrences causally related to treatment / all	0 / 6	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 1	
femoral neck fracture			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
femur fracture			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
forearm fracture			
alternative dictionary used: MedDRA 18.0			

subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
head injury			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
hip fracture			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	2 / 106 (1.89%)	4 / 110 (3.64%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
humerus fracture			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
lumbar vertebral fracture			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
pelvic fracture			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	0 / 106 (0.00%)	2 / 110 (1.82%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
rib fracture			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

subdural haematoma alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 106 (0.00%) 0 / 0 0 / 0	1 / 110 (0.91%) 0 / 1 0 / 0	
Cardiac disorders bradycardia alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 106 (0.00%) 0 / 0 0 / 0	1 / 110 (0.91%) 0 / 1 0 / 0	
cardiac failure alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 106 (0.94%) 0 / 1 0 / 0	0 / 110 (0.00%) 0 / 0 0 / 0	
cardiac failure congestive alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 106 (0.00%) 0 / 0 0 / 0	2 / 110 (1.82%) 0 / 2 0 / 2	
mitral valve incompetence alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 106 (0.00%) 0 / 0 0 / 0	1 / 110 (0.91%) 0 / 1 0 / 1	
Nervous system disorders amnesia alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all  cerebral infarction alternative dictionary used: MedDRA 18.0	1 / 106 (0.94%) 0 / 1 0 / 0   	0 / 110 (0.00%) 0 / 0 0 / 0   	



subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
cerebrovascular accident			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	0 / 106 (0.00%)	2 / 110 (1.82%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
headache			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ischaemic stroke			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
monoplegia			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
speech disorder			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
syncope			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

<p>Eye disorders</p> <p>retinal detachment</p> <p>alternative dictionary used: MedDRA 18.0</p> <p>subjects affected / exposed</p> <p>occurrences causally related to treatment / all</p> <p>deaths causally related to treatment / all</p>	<p>0 / 106 (0.00%)</p> <p>0 / 0</p> <p>0 / 0</p>	<p>1 / 110 (0.91%)</p> <p>0 / 2</p> <p>0 / 0</p>	
<p>Gastrointestinal disorders</p> <p>oedema mouth</p> <p>alternative dictionary used: MedDRA 18.0</p> <p>subjects affected / exposed</p> <p>occurrences causally related to treatment / all</p> <p>deaths causally related to treatment / all</p>	<p>0 / 106 (0.00%)</p> <p>0 / 0</p> <p>0 / 0</p>	<p>1 / 110 (0.91%)</p> <p>0 / 1</p> <p>0 / 0</p>	
<p>Hepatobiliary disorders</p> <p>liver disorder</p> <p>alternative dictionary used: MedDRA 18.0</p> <p>subjects affected / exposed</p> <p>occurrences causally related to treatment / all</p> <p>deaths causally related to treatment / all</p>	<p>1 / 106 (0.94%)</p> <p>0 / 1</p> <p>0 / 0</p>	<p>0 / 110 (0.00%)</p> <p>0 / 0</p> <p>0 / 0</p>	
<p>Musculoskeletal and connective tissue disorders</p> <p>arthralgia</p> <p>alternative dictionary used: MedDRA 18.0</p> <p>subjects affected / exposed</p> <p>occurrences causally related to treatment / all</p> <p>deaths causally related to treatment / all</p>	<p>3 / 106 (2.83%)</p> <p>0 / 3</p> <p>0 / 0</p>	<p>0 / 110 (0.00%)</p> <p>0 / 0</p> <p>0 / 0</p>	
<p>back pain</p> <p>alternative dictionary used: MedDRA 18.0</p> <p>subjects affected / exposed</p> <p>occurrences causally related to treatment / all</p> <p>deaths causally related to treatment / all</p>	<p>1 / 106 (0.94%)</p> <p>0 / 1</p> <p>0 / 0</p>	<p>0 / 110 (0.00%)</p> <p>0 / 0</p> <p>0 / 0</p>	
<p>Infections and infestations</p> <p>gastroenteritis</p> <p>alternative dictionary used: MedDRA 18.0</p>			

subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pneumonia			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
postoperative wound infection			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
septic shock			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
subcutaneous abscess			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	0 / 106 (0.00%)	1 / 110 (0.91%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
urinary tract infection			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	2 / 110 (1.82%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
wound infection staphylococcal			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Metabolism and nutrition disorders			
dehydration			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hyperglycaemia			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
type 2 diabetes mellitus			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	0 / 110 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 1 %

<b>Non-serious adverse events</b>	Teriparatide	Risedronate	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	53 / 106 (50.00%)	47 / 110 (42.73%)	
Vascular disorders			
hypertension			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	5 / 106 (4.72%)	2 / 110 (1.82%)	
occurrences (all)	5	2	
Reproductive system and breast disorders			
benign prostatic hyperplasia			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed <sup>[1]</sup>	0 / 106 (0.00%)	1 / 23 (4.35%)	
occurrences (all)	0	1	
vulval ulceration			
alternative dictionary used: MedDRA 18.0			

<p>subjects affected / exposed<sup>[2]</sup></p> <p>0 / 106 (0.00%)</p> <p>1 / 87 (1.15%)</p> <p>occurrences (all)</p> <p>0</p> <p>1</p> <p>vulvovaginal dryness</p> <p>alternative dictionary used: MedDRA 18.0</p> <p>subjects affected / exposed<sup>[3]</sup></p> <p>1 / 81 (1.23%)</p> <p>0 / 110 (0.00%)</p> <p>occurrences (all)</p> <p>1</p> <p>0</p>			
<p>Psychiatric disorders</p> <p>delirium</p> <p>alternative dictionary used: MedDRA 18.0</p> <p>subjects affected / exposed</p> <p>2 / 106 (1.89%)</p> <p>0 / 110 (0.00%)</p> <p>occurrences (all)</p> <p>2</p> <p>0</p> <p>depression</p> <p>alternative dictionary used: MedDRA 18.0</p> <p>subjects affected / exposed</p> <p>1 / 106 (0.94%)</p> <p>3 / 110 (2.73%)</p> <p>occurrences (all)</p> <p>1</p> <p>3</p> <p>insomnia</p> <p>alternative dictionary used: MedDRA 18.0</p> <p>subjects affected / exposed</p> <p>3 / 106 (2.83%)</p> <p>1 / 110 (0.91%)</p> <p>occurrences (all)</p> <p>3</p> <p>1</p>			
<p>Investigations</p> <p>blood creatine phosphokinase increased</p> <p>alternative dictionary used: MedDRA 18.0</p> <p>subjects affected / exposed</p> <p>2 / 106 (1.89%)</p> <p>0 / 110 (0.00%)</p> <p>occurrences (all)</p> <p>2</p> <p>0</p> <p>platelet count increased</p> <p>alternative dictionary used: MedDRA 18.0</p> <p>subjects affected / exposed</p> <p>2 / 106 (1.89%)</p> <p>0 / 110 (0.00%)</p> <p>occurrences (all)</p> <p>2</p> <p>0</p>			
<p>Injury, poisoning and procedural complications</p> <p>fall</p> <p>alternative dictionary used: MedDRA 18.0</p> <p>subjects affected / exposed</p> <p>7 / 106 (6.60%)</p> <p>5 / 110 (4.55%)</p> <p>occurrences (all)</p> <p>8</p> <p>5</p>			
Nervous system disorders			

dizziness alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 2	1 / 110 (0.91%) 1	
headache alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 2	0 / 110 (0.00%) 0	
Blood and lymphatic system disorders anaemia alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences (all)	0 / 106 (0.00%) 0	2 / 110 (1.82%) 2	
Gastrointestinal disorders abdominal pain upper alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences (all)	3 / 106 (2.83%) 3	1 / 110 (0.91%) 1	
constipation alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 2	3 / 110 (2.73%) 3	
diarrhoea alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences (all)	3 / 106 (2.83%) 3	0 / 110 (0.00%) 0	
nausea alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 6	0 / 110 (0.00%) 0	
Skin and subcutaneous tissue disorders eczema alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences (all)	2 / 106 (1.89%) 2	0 / 110 (0.00%) 0	
rash			

alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	2 / 110 (1.82%) 2	
Renal and urinary disorders urinary incontinence alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences (all)	1 / 106 (0.94%) 1	2 / 110 (1.82%) 2	
Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences (all)  back pain alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences (all)  bone pain alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences (all)  groin pain alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences (all)  musculoskeletal pain alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences (all)  pain in extremity alternative dictionary used: MedDRA 18.0 subjects affected / exposed occurrences (all)  osteoarthritis alternative dictionary used:	12 / 106 (11.32%) 16  3 / 106 (2.83%) 6  0 / 106 (0.00%) 0  1 / 106 (0.94%) 1  2 / 106 (1.89%) 2  3 / 106 (2.83%) 7	7 / 110 (6.36%) 8  3 / 110 (2.73%) 3  2 / 110 (1.82%) 2  2 / 110 (1.82%) 2  1 / 110 (0.91%) 1  2 / 110 (1.82%) 3	

MedDRA 18.0			
subjects affected / exposed	2 / 106 (1.89%)	2 / 110 (1.82%)	
occurrences (all)	2	2	
Infections and infestations			
bronchitis			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	4 / 106 (3.77%)	0 / 110 (0.00%)	
occurrences (all)	4	0	
gastroenteritis			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	2 / 106 (1.89%)	0 / 110 (0.00%)	
occurrences (all)	2	0	
influenza			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	2 / 106 (1.89%)	1 / 110 (0.91%)	
occurrences (all)	2	1	
nasopharyngitis			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	2 / 106 (1.89%)	2 / 110 (1.82%)	
occurrences (all)	2	2	
urinary tract infection			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	7 / 106 (6.60%)	4 / 110 (3.64%)	
occurrences (all)	7	7	
viral infection			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	3 / 106 (2.83%)	0 / 110 (0.00%)	
occurrences (all)	4	0	
Metabolism and nutrition disorders			
hypercalcaemia			
alternative dictionary used: MedDRA 18.0			
subjects affected / exposed	1 / 106 (0.94%)	2 / 110 (1.82%)	
occurrences (all)	1	2	

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects



exposed for the reporting group. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male or female subjects. The number of subjects exposed has been adjusted accordingly.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male or female subjects. The number of subjects exposed has been adjusted accordingly.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: This event is gender specific, only occurring in male or female subjects. The number of subjects exposed has been adjusted accordingly.

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported